Look back at pharma news in week to March 15

17 March 2019

By Barbara Obstoj-Cardwell. Editor

On the research front last week, there was positive clinical trial news for Takeda regarding its Entyvio in ulcerative colitis. Regulatory news of note included Roche winning US Food and Drug Administration approval for its Tecentriq as the first immuno-oncology treatment for breast cancer, and an FDA delay for multiple myeloma drug selinexor which, unusually, was viewed as good news for developer Karyopharm Therapeutics. Elsewhere, the CARB-X incubator got a boost with the German government joining up and providing funding for the development of antibacterials.

Takeda’s Entyvio beats AbbVie’s Humira in head-to-head UC study

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK